Nutra Pharma Corp.
Bringing Healthcare Solutions to the World
 
Newsroom
Recent News
Archives
E-Alerts
Press Kit
Drug Development
R&D Pipeline
Nutra Pharma is developing an innovative pipeline of biopharmaceutical products
E-Alerts
Signup to receive news and announcements from Nutra Pharma:
First Name:
Last Name:
Email:
Infinite Menus, Copyright 2006, OpenCube Inc. All Rights Reserved.

Newsroom

Nutra Pharma Announces Svizera Labs to Supply Designer Diagnostics' Test Kits to the World Health Organization
March 31, 2006

Nutra Pharma Corp., a biotechnology company that is developing drugs for HIV and Multiple Sclerosis, has announced that Designer Diagnostics, a wholly owned subsidiary of Nutra Pharma, and Svizera Labs have agreed in principal to supply Designer Diagnostics' Test Kits to the World Health Organization (WHO). Svizera will begin distribution of the kits after completion of a series of required testing and analysis. Svizera is currently the exclusive provider of tuberculosis test kits to WHO. Svizera also provides 60% of the antibiotics for the treatment of tuberculosis to WHO.

"The planned partnership with Svizera is an incredible opportunity for Designer Diagnostics. It will allow us to distribute our diagnostic test kits directly where they are needed most," explained Neil Roth, President of Designer Diagnostics. "We expect distribution as soon as the testing and analysis requirements for WHO are met and then to grow the distribution levels dramatically over the next twelve months," he concluded.

In 2005, Svizera distributed over 15 million diagnostic test kits to WHO. Details of the Designer Diagnostics agreement include replacing the current tuberculosis diagnostic test kits being distributed by Svizera with the introduction of the Designer Diagnostics NTM Test Kit and antibiotic sensitivity kits.

SEC Disclaimer

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The agreement with Svizera Labs should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.


 
Quick Nav
Nyloxin // Chronic Pain Relief
Read about Jeff Gottfurcht, the first rheumatoid arthritis sufferer to conquer Everest, in Musculoskeletal Health a special section of the Washington Post.
 

 

 
Recent News
 
May 23, 2017
Nutra Pharma Announces Collaboration with the International Security Group for Development of Nerve Agent Counter Measures


March 14, 2017
Nutra Pharma CEO Rik Deitsch Interviewed by Stockguru.com


February 22, 2017
Global Small Caps Initiates Coverage on Nutra Pharma


 
 
Announcements
Click here to view a Letter to Shareholders from the Company's CEO, Rik J Deitsch.
 
 
Facebook   Twitter
 
NPC
Privacy Policy Code of Ethics